Menu

Building the next generation of healthcare companies

Delivering transformational treatments to patients Generating superior returns for shareholders

Who we are

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Investors

Syncona is a FTSE250 business listed on the London Stock Exchange. Find the latest share price, announcements, presentations and events here.

Our portfolio

A selective portfolio of high quality healthcare businesses in truly innovative areas of science

Learn more

Transformational treatments

As we seek to build companies in truly innovative areas in healthcare, our ultimate goal is to deliver transformational treatments to patients, enabling them to continue enjoying their lives

Learn more

Achilles Therapeutics and the advent of immunotherapy

Syncona speaks to Achilles Therapeutics' clinical founder Charlie Swanton about his career, the advent of immunotherapy, and what he wants Achilles to achieve.

Emma Salisbury - measuring the potential impact of gene therapy

Emma Salisbury, mother of Tommy Salisbury, tells us about the impact of Choroideremia and the potential of gene therapy.

Latest news

View all
Blue Earth Diagnostics Announces Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming American Urological Association’s 2019 Annual Meeting
24.04.2019
View
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
23.04.2019
View
Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer
16.04.2019
View
Blue Earth Diagnostics celebrates five year anniversary
06.03.2019
View